Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-1,3-N-acetylgalactosaminyltransferase 1 pseudogene 1 is a processed pseudogene that is related to the parental gene beta-1,3-N-acetylgalactosaminyltransferase 1 (B3GALNT1). Like other pseudogenes, it is a DNA sequence that closely resembles the protein-coding gene but has acquired mutations or sequence changes that prevent it from producing a functional protein. In general, pseudogenes can sometimes play regulatory roles at the RNA level—such as acting as decoys for microRNAs or as modulators of parental gene expression—but no such function has specifically been attributed to B3GALNT1P1 to date. This gene is not a therapeutic, diagnostic, or prognostic target and has no direct involvement with drug action, disease mechanisms, or safety considerations. Its primary importance lies in the context of genome annotation and evolutionary genetics.
None applicable (not a protein; no drugs target it directly)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-1,3-N-acetylgalactosaminyltransferase 1 pseudogene 1 (B3GALNT1P1).